CASE STUDIES

Controversy regarding the use of metformin in diabetic patients with chronic kidney disease stage 2 and 3

by

Valérie Gras-Champel, Aline Munier and Ziad A. Massy

Dr Valérie Gras-Champel
Clinical Pharmacology
University Hospital of Amiens
Amiens, France
Prof Z.A. Massy
Nephrology and Clinical Pharmacology Departments
University Hospital of Amiens
Amiens, France

 

 

An 85-year-old woman weighing 65kg, was admitted to the intensive care unit of our hospital for vomiting, abdominal pain, discomfort, confusion and dyspnea, which had lasted for 48 hours. She had a history of diarrhea several days before her admission with favorable spontaneous evolution. At this time she self-administered aspirin (3g/day) for a few days. She was currently being treated with metformin (2 x 850 mg/day) and simvastatin (10 mg/day) for type-2 diabetes and hypercholesterolemia respectively.
At admission, physical examination showed body temperature of 37°, and normal blood pressure. Plasma electrolyte levels were considered normal: sodium=145 mEq/L; potassium=5.1 mEq/L, chloride=102 mEq/L. Arterial blood gas analysis showed: pH=7.1; pCO2 =14.4 mmHg; pO2=134.2 mmHg; HCO3-=4.4 mmol/L. Additional blood tests demonstrated: creatininemia=130 µmol/L; glucose = 5 mmol/L; blood lactatemia=33 mmol/L; ketonemia= 0.3 mmol/L, ketonuria=1.10 mmol/24h; transaminases=120 UI/L; TP=90%. White blood cells=5200/mm3.

Chemical structure of two members of the biguanid family.

 

QUESTIONS

 

REFERENCES

1. Jones GC, Macklin JP, Alexander WD. Contraindications to the use of metformin. Br Med J 2003; 326: 4-5. Pubmed Link
2. Lalau JD, Race JM. Lactic Acidosis in Metformin-Treated Patients – Prognostic Value of Arterial Lactate Levels and Plasma Metformin Concentrations. Drug Saf 1999; 20 (4): 377-384. Pubmed Link
3. Chang C, Chen YC, Fang JT, Huang CC. Metformin-associated lactic acidosis: case reports and literature review. J Nephrol 2000; 15: 398-402.
4. Lalau JD, Race JM. Metformine and lactic acidosis in diabetic humans. Diabetes Obesity Metab, 2000; 2: 131-137. Pubmed Link
5. Salpeter SR, Greyber E, Pasternak GA, Salpeter EE. Risk of fatal and nonfatal lactic acidosis with metformin use in type 2 diabetes mellitus: systematic review and meta-analysis. Arch Intern Med 2003; 163 (21): 2594-602. Pubmed Link
6. Trischitta V, Gullo D, Pezzino V, Vigneri R. Metformin Normalizes Insulin Binding to Moncytes from Obese Nondiabetic Subjects and Obes Type II Diabetic Patients. J Clin Endocrinol Metab 1983; 57 (4); 713-718. Pubmed Link
7. Menzies DG, Campbell IW, McBain A, Brown IR. Metformin efficacy and tolerance in obese non-insulin dependent diabetics: a comparison of two dosage schedules. Curr Med Res Opin 1989; 11 (5); 273-278. Pubmed Link
8. Lalau JD, Vermersch A, Hary L, Andrejak M, Isnard F, Quichaud J. Type 2 diabetes in elderly: an assessment of metformin. Int J Clin Pharmacol Ther Toxicol 1990; 28: 329-332. Pubmed Link
9. UK Prospective Diabetes Study (UKPDS) Group. Effect of intensive blood-glucose control with metformin on complication in overweight patients with type 2 diabetes (UKPDS 34). Lancet 1998; 352: 854-865. Pubmed Link

Acknowledgements: The author is indebted to Prof Michel Andrejak, and Dr Henri Masson for revising the manuscript and making useful suggestions, as well as Prof Jean-Daniel Lalau for his useful help regarding the bibliography.